Is Your Fertility Doctor Taking Kickbacks?
By Cassie Murdoch,
Slate
| 07. 13. 2012
People take out loans to buy a car or a house or to send a child (or themselves) to college. And these days, more and more people are also taking out loans to create babies. It makes sense: A single cycle of IVF can run about $12,000, which, for most people, is A LOT of money. Responding to the growing IVF market, companies that give loans to fund fertility treatments are sprouting up across the country.
The
Today Show’s Dr. Nancy Snyderman recently
filed a report about the dozens of these fertility finance companies that are changing the way couples think about their options for having children. In theory, they’re just like any other loan company—except that they’re dealing with a population of borrowers who are often far more emotionally vulnerable than your average home buyer, and many of these lenders seem totally comfortable taking advantage of that fact. There are some that charge exorbitant interest rates, and others that are engaging in something far more unethical: Snyderman reports that some lenders are giving fertility doctors kickbacks or a...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...